My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Fate Therapeutics, Inc. - Common Stock (NQ:FATE)

0.9701 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 177
Open 0.9701
Bid (Size) 0.9700 (24)
Ask (Size) 1.010 (25)
Prev. Close 0.9701
Today's Range 0.9701 - 0.9701
52wk Range 0.6611 - 3.900
Shares Outstanding 98,384,456
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics to Present at Upcoming Investor Conferences
From Fate Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-45.8%
-45.8%
1 Month
-11.0%
-11.0%
3 Month
-17.1%
-17.1%
6 Month
+7.5%
+7.5%
1 Year
-73.3%
-73.3%

More News

Read More
FATE THERAPEUTICS INC (NASDAQ:FATE) Reports Mixed Q2 2025 Results with Revenue Beat and Narrower Loss
Via Chartmill
Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress
From Fate Therapeutics, Inc.
Via GlobeNewswire
4 Analysts Assess Fate Therapeutics: What You Need To Know
Via Benzinga
Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting
From Fate Therapeutics, Inc.
Via GlobeNewswire
Gapping stocks in Monday's session
Via Chartmill
Fate Therapeutics Stock Draws Investor Attention After FDA Grants Special Designation To Its CAR T-Cell Therapy: Retail Stays Optimistic
Via Stocktwits
Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Curious about the stocks that are showing activity after the closing bell on Wednesday?
Via Chartmill
Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics to Present at Upcoming Investor Conferences
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Fate Therapeutics, Inc. - Common Stock publicly traded?
Yes, Fate Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Fate Therapeutics, Inc. - Common Stock trade on?
Fate Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Fate Therapeutics, Inc. - Common Stock?
The ticker symbol for Fate Therapeutics, Inc. - Common Stock is FATE on the Nasdaq Stock Market
What is the current price of Fate Therapeutics, Inc. - Common Stock?
The current price of Fate Therapeutics, Inc. - Common Stock is 0.9701
When was Fate Therapeutics, Inc. - Common Stock last traded?
The last trade of Fate Therapeutics, Inc. - Common Stock was at 09/23/25 04:00 PM ET
What is the market capitalization of Fate Therapeutics, Inc. - Common Stock?
The market capitalization of Fate Therapeutics, Inc. - Common Stock is 95.44M
How many shares of Fate Therapeutics, Inc. - Common Stock are outstanding?
Fate Therapeutics, Inc. - Common Stock has 95M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.